Index RUT
P/E -
EPS (ttm) -2.90
Insider Own 2.37%
Shs Outstand 69.93M
Perf Week -3.58%
Market Cap 1.45B
Forward P/E -
EPS next Y -3.24
Insider Trans -3.25%
Shs Float 68.27M
Perf Month 2.67%
Income -177.37M
PEG -
EPS next Q -0.98
Inst Own 89.77%
Short Float 7.85%
Perf Quarter -2.44%
Sales 133.62M
P/S 10.86
EPS this Y -90.05%
Inst Trans -2.04%
Short Ratio 10.31
Perf Half Y 9.10%
Book/sh 9.14
P/B 2.27
EPS next Y 17.97%
ROA -22.11%
Short Interest 5.36M
Perf Year 15.99%
Cash/sh 7.27
P/C 2.85
EPS next 5Y -
ROE -28.53%
52W Range 15.31 - 26.84
Perf YTD -2.26%
Dividend Est. -
P/FCF 55.05
EPS past 5Y -9.81%
ROI -27.55%
52W High -22.69%
Beta 0.67
Dividend TTM -
Quick Ratio 6.92
Sales past 5Y 70.11%
Gross Margin 90.70%
52W Low 35.53%
ATR (14) 0.81
Dividend Ex-Date -
Current Ratio 6.92
EPS Y/Y TTM -35.72%
Oper. Margin -128.78%
RSI (14) 53.36
Volatility 3.08% 3.61%
Employees 280
Debt/Eq 0.16
Sales Y/Y TTM 17.84%
Profit Margin -132.74%
Recom 1.55
Target Price 31.40
Option/Short Yes / Yes
LT Debt/Eq 0.14
EPS Q/Q -191.34%
Payout -
Rel Volume 0.47
Prev Close 21.23
Sales Surprise -15.20%
EPS Surprise -28.78%
Sales Q/Q -62.74%
Earnings Aug 05 AMC
Avg Volume 519.76K
Price 20.75
SMA20 1.37%
SMA50 7.68%
SMA200 0.90%
Trades
Volume 178,234
Change -2.26%
Date
Action
Analyst
Rating Change
Price Target Change
Apr-16-24 Reiterated
BTIG Research
Buy
$56 → $38
Feb-28-24 Downgrade
Piper Sandler
Overweight → Neutral
$37 → $24
May-19-23 Initiated
BofA Securities
Buy
$42
Dec-06-22 Initiated
Cowen
Outperform
Oct-13-22 Upgrade
Raymond James
Outperform → Strong Buy
$58
Sep-21-22 Initiated
JP Morgan
Overweight
$37
Jul-06-22 Resumed
Canaccord Genuity
Buy
$50
Feb-11-22 Initiated
BMO Capital Markets
Outperform
$54
Jan-21-22 Initiated
SMBC Nikko
Outperform
$60
Dec-15-21 Initiated
H.C. Wainwright
Buy
$61
Oct-15-21 Resumed
BTIG Research
Buy
$56
Feb-24-21 Upgrade
Raymond James
Mkt Perform → Outperform
$58
Mar-04-20 Initiated
Barclays
Underweight
$28
Feb-25-20 Upgrade
Guggenheim
Neutral → Buy
$43
Jan-30-20 Initiated
RBC Capital Mkts
Outperform
$44
Nov-20-19 Resumed
Guggenheim
Neutral
Aug-07-19 Downgrade
Raymond James
Outperform → Mkt Perform
Aug-07-19 Downgrade
Guggenheim
Buy → Neutral
Jun-13-19 Initiated
Mizuho
Buy
Apr-12-19 Initiated
Guggenheim
Buy
Show Previous Ratings
Oct-18-24 03:05PM
Oct-16-24 09:55AM
Oct-10-24 08:09AM
Oct-04-24 08:01AM
Sep-12-24 04:01PM
04:55AM
Loading…
04:55AM
Sep-11-24 06:31AM
Sep-10-24 04:01PM
Sep-09-24 07:31AM
Sep-06-24 08:01AM
Aug-05-24 09:55PM
05:15PM
04:12PM
(Associated Press Finance)
04:01PM
Jun-13-24 08:01AM
01:45PM
Loading…
May-10-24 01:45PM
06:20AM
May-09-24 11:54PM
05:18PM
(Associated Press Finance)
04:09PM
May-06-24 10:00AM
May-03-24 07:01PM
May-02-24 03:31AM
Apr-09-24 08:01AM
Mar-08-24 05:01PM
Mar-07-24 05:00PM
Feb-28-24 04:01PM
09:35AM
(Thomson Reuters StreetEvents)
08:38AM
Feb-27-24 05:20PM
04:39PM
Loading…
04:39PM
04:26PM
(Associated Press Finance)
04:01PM
Feb-20-24 04:31PM
Feb-19-24 03:37AM
Feb-15-24 10:00AM
Jan-03-24 04:01PM
09:55AM
Jan-02-24 08:01AM
Dec-30-23 05:02PM
Nov-21-23 04:01PM
Nov-09-23 02:19PM
Nov-08-23 05:21AM
(FierceBiotech.com) -7.01%
Nov-07-23 04:39PM
(Associated Press Finance)
04:01PM
04:01PM
Nov-03-23 12:01PM
Oct-31-23 04:01PM
12:00PM
Oct-26-23 08:01AM
Oct-17-23 04:21AM
Sep-27-23 09:01AM
Sep-19-23 04:01PM
Aug-08-23 06:01AM
Aug-07-23 04:02PM
Aug-03-23 05:15PM
04:13PM
(Associated Press Finance)
04:01PM
Jul-27-23 08:01AM
Jul-03-23 08:38PM
Jun-21-23 08:00PM
Jun-18-23 10:00AM
May-30-23 06:01PM
May-09-23 01:49PM
(Thomson Reuters StreetEvents)
May-08-23 05:15PM
04:08PM
04:01PM
May-01-23 04:01PM
Apr-26-23 08:00PM
08:01AM
Apr-17-23 01:31PM
Apr-09-23 01:19PM
Mar-14-23 04:31PM
02:56AM
Feb-28-23 05:10AM
Feb-25-23 07:17AM
Feb-23-23 05:25PM
04:01PM
Feb-20-23 10:00AM
Feb-16-23 04:01PM
Feb-07-23 04:01PM
Jan-26-23 02:33PM
Jan-09-23 08:01AM
Jan-05-23 06:30AM
Jan-04-23 04:01PM
Dec-12-22 03:44PM
10:00AM
Nov-30-22 09:55AM
Nov-25-22 12:00PM
Nov-10-22 04:01PM
09:55AM
09:01AM
Nov-07-22 05:25PM
04:01PM
04:01PM
Nov-03-22 09:01AM
Oct-31-22 04:01PM
Oct-28-22 11:58AM
Oct-14-22 09:41AM
Oct-06-22 08:37PM
Xencor, Inc. is a biopharmaceutical company, which engages in the development of engineered monoclonal antibody therapeutics to treat severe and life-threatening diseases. Its proprietary technology platform, XmAb, is used to create next-generation antibody product candidates designed to treat autoimmune and allergic diseases, cancer, and other conditions. The company was founded by Bassil I. Dahiyat and Stephen L. Mayo in August 1997 and is headquartered in Monrovia, CA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
ROSA-BJORKESON DAGMAR Director Sep 27 '24 Sale 20.68 2,503 51,762 8,490 Oct 01 04:13 PM RANIERI RICHARD J Director Sep 27 '24 Sale 20.68 2,503 51,762 8,490 Oct 01 04:12 PM GUSTAFSON KURT A Director Sep 27 '24 Sale 20.68 2,503 51,762 9,490 Oct 01 04:10 PM GORMAN KEVIN CHARLES Director Sep 27 '24 Sale 20.68 2,654 54,885 8,392 Oct 01 04:09 PM Montgomery Alan Bruce Director Sep 27 '24 Sale 20.68 1,853 38,320 9,140 Oct 01 04:08 PM Feigal Ellen Director Sep 27 '24 Sale 20.68 2,503 51,762 8,490 Oct 01 04:07 PM GORMAN KEVIN CHARLES Director Sep 27 '24 Proposed Sale 20.68 2,654 54,885 Sep 27 10:58 AM Montgomery Alan Bruce Director Sep 27 '24 Proposed Sale 20.68 1,853 38,320 Sep 27 10:39 AM Feigal Ellen Director Sep 27 '24 Proposed Sale 20.68 2,503 51,762 Sep 27 10:35 AM RANIERI RICHARD J Director Sep 27 '24 Proposed Sale 20.68 2,503 51,762 Sep 27 10:29 AM GUSTAFSON KURT A Director Sep 27 '24 Proposed Sale 20.68 2,503 51,762 Sep 27 10:12 AM ROSA-BJORKESON DAGMAR Director Sep 27 '24 Proposed Sale 20.68 2,503 51,762 Sep 27 09:41 AM Desjarlais John R SR. VICE PRESIDENT & CSO Jul 09 '24 Option Exercise 10.73 42,215 452,967 228,648 Jul 11 06:41 PM Desjarlais John R SR. VICE PRESIDENT & CSO Jul 10 '24 Option Exercise 10.73 7,785 83,533 200,104 Jul 11 06:41 PM Desjarlais John R SR. VICE PRESIDENT & CSO Jul 09 '24 Sale 18.32 36,329 665,511 192,319 Jul 11 06:41 PM Valente Nancy EVP, Chief Development Officer May 02 '24 Sale 23.58 4,745 111,872 55,115 May 03 04:06 PM Kuch John J SR. VICE PRESIDENT & CFO Mar 11 '24 Sale 23.50 849 19,953 121,070 Mar 12 04:08 PM Eckert Celia SVP, GENERAL COUNSEL Mar 11 '24 Sale 23.50 850 19,977 45,465 Mar 12 04:06 PM Desjarlais John R SR. VICE PRESIDENT & CSO Mar 11 '24 Sale 23.50 1,280 30,082 186,433 Mar 12 04:05 PM Dahiyat Bassil I PRESIDENT & CEO Mar 11 '24 Sale 23.50 2,741 64,418 351,894 Mar 12 04:03 PM GUSTAFSON KURT A Director Mar 06 '24 Option Exercise 10.73 15,000 160,950 20,007 Mar 07 04:10 PM GUSTAFSON KURT A Director Mar 06 '24 Sale 23.18 14,000 324,453 6,007 Mar 07 04:10 PM Kuch John J SR. VICE PRESIDENT & CFO Mar 05 '24 Sale 23.43 4,474 104,821 121,919 Mar 07 04:07 PM Desjarlais John R SR. VICE PRESIDENT & CSO Mar 05 '24 Sale 23.43 6,629 155,311 166,989 Mar 07 04:05 PM Eckert Celia SVP, GENERAL COUNSEL Mar 05 '24 Sale 23.43 3,892 91,186 33,226 Mar 07 04:03 PM Dahiyat Bassil I PRESIDENT & CEO Mar 05 '24 Sale 23.43 12,528 293,519 300,097 Mar 07 04:01 PM Desjarlais John R SR. VICE PRESIDENT & CSO Feb 14 '24 Option Exercise 11.05 11,943 131,970 173,618 Feb 16 04:06 PM GORMAN KEVIN CHARLES Director Feb 13 '24 Buy 19.12 53 1,013 5,060 Feb 15 04:02 PM Desjarlais John R SR. VICE PRESIDENT & CSO Feb 13 '24 Option Exercise 11.05 68,057 752,030 215,783 Feb 14 02:23 PM Desjarlais John R SR. VICE PRESIDENT & CSO Feb 13 '24 Sale 19.38 54,108 1,048,743 161,675 Feb 14 02:23 PM Dahiyat Bassil I PRESIDENT & CEO Dec 29 '23 Option Exercise 11.05 65,001 718,261 357,929 Dec 29 04:24 PM Dahiyat Bassil I PRESIDENT & CEO Dec 29 '23 Sale 20.93 45,000 941,670 312,929 Dec 29 04:24 PM
Index -
P/E 34.68
EPS (ttm) 3.31
Insider Own 2.17%
Shs Outstand 100.98M
Perf Week -3.00%
Market Cap 11.59B
Forward P/E 16.86
EPS next Y 6.81
Insider Trans -7.46%
Shs Float 98.78M
Perf Month -1.45%
Income 339.20M
PEG 0.85
EPS next Q 1.52
Inst Own 93.79%
Short Float 2.48%
Perf Quarter -21.42%
Sales 2.12B
P/S 5.47
EPS this Y 93.40%
Inst Trans 0.53%
Short Ratio 2.65
Perf Half Y -17.39%
Book/sh 24.87
P/B 4.62
EPS next Y 42.58%
ROA 11.46%
Short Interest 2.45M
Perf Year 6.38%
Cash/sh 10.29
P/C 11.16
EPS next 5Y 41.00%
ROE 15.55%
52W Range 103.63 - 157.98
Perf YTD -12.87%
Dividend Est. -
P/FCF 23.44
EPS past 5Y 62.04%
ROI 12.27%
52W High -27.33%
Beta 0.36
Dividend TTM -
Quick Ratio 4.08
Sales past 5Y 34.77%
Gross Margin 97.28%
52W Low 10.78%
ATR (14) 2.43
Dividend Ex-Date Dec 29, 1995
Current Ratio 4.19
EPS Y/Y TTM 87.53%
Oper. Margin 25.70%
RSI (14) 40.13
Volatility 1.63% 1.82%
Employees 1400
Debt/Eq 0.12
Sales Y/Y TTM 26.69%
Profit Margin 16.00%
Recom 1.45
Target Price 164.04
Option/Short Yes / Yes
LT Debt/Eq 0.10
EPS Q/Q -34.36%
Payout 0.00%
Rel Volume 0.37
Prev Close 116.78
Sales Surprise 8.10%
EPS Surprise -44.16%
Sales Q/Q 30.37%
Earnings Oct 30 BMO
Avg Volume 926.28K
Price 114.80
SMA20 -0.19%
SMA50 -7.77%
SMA200 -15.07%
Trades
Volume 250,278
Change -1.70%
Date
Action
Analyst
Rating Change
Price Target Change
Oct-10-24 Resumed
Raymond James
Outperform
$155
Aug-29-24 Upgrade
Piper Sandler
Neutral → Overweight
$131 → $159
Apr-24-24 Upgrade
Wells Fargo
Equal Weight → Overweight
$140 → $170
Dec-13-23 Resumed
Citigroup
Neutral
$127
Dec-12-23 Initiated
Deutsche Bank
Buy
$136
Oct-24-23 Resumed
Cantor Fitzgerald
Overweight
$135 → $140
Aug-21-23 Reiterated
Mizuho
Neutral
$112 → $113
Jul-24-23 Upgrade
SVB Securities
Market Perform → Outperform
$115 → $125
Jul-06-23 Upgrade
BMO Capital Markets
Underperform → Market Perform
$91 → $96
May-04-23 Upgrade
Guggenheim
Neutral → Buy
$145
Mar-30-23 Upgrade
Canaccord Genuity
Hold → Buy
$124 → $132
Mar-03-23 Upgrade
Evercore ISI
In-line → Outperform
$130
Feb-03-23 Upgrade
Morgan Stanley
Equal-Weight → Overweight
$120 → $130
Nov-14-22 Downgrade
Evercore ISI
Outperform → In-line
$140 → $130
Oct-11-22 Initiated
UBS
Buy
$136
Sep-26-22 Initiated
Wells Fargo
Equal Weight
$110
Jun-06-22 Resumed
Jefferies
Buy
$126 → $112
Mar-03-22 Downgrade
Piper Sandler
Overweight → Neutral
$114 → $94
Feb-25-22 Upgrade
Goldman
Neutral → Buy
$115
Jan-18-22 Downgrade
RBC Capital Mkts
Outperform → Sector Perform
$122 → $90
Show Previous Ratings
Today 10:56AM
10:01AM
Oct-17-24 01:02PM
Oct-16-24 04:04PM
Oct-09-24 04:01PM
08:30AM
Loading…
Sep-30-24 08:30AM
Sep-19-24 04:01PM
Sep-14-24 07:25PM
Sep-13-24 04:32AM
Sep-12-24 04:05PM
Sep-10-24 04:01PM
Sep-02-24 10:53AM
(Pharmaceutical Technology)
Aug-30-24 07:41AM
Aug-29-24 01:22PM
06:52AM
06:19PM
Loading…
Aug-28-24 06:19PM
04:28PM
(Investor's Business Daily)
04:05PM
11:16AM
09:56AM
(Investor's Business Daily)
08:17AM
(Investor's Business Daily)
08:15AM
07:07AM
07:00AM
Aug-16-24 07:01PM
Aug-07-24 04:01PM
Aug-06-24 12:45PM
Aug-02-24 06:39AM
01:05AM
Aug-01-24 10:00AM
08:06AM
Loading…
08:06AM
08:05AM
07:09AM
(Associated Press Finance)
07:00AM
Jul-31-24 09:15AM
Jul-25-24 10:02AM
Jul-18-24 08:30AM
Jul-12-24 08:38AM
Jul-11-24 04:01PM
Jul-02-24 06:33AM
(Pharmaceutical Technology)
Jul-01-24 07:30AM
Jun-28-24 04:37PM
Jun-17-24 03:27PM
Jun-14-24 02:34PM
(Investor's Business Daily)
Jun-03-24 08:01AM
07:35AM
07:30AM
May-29-24 04:01PM
May-28-24 04:14PM
08:30AM
May-21-24 04:05PM
May-16-24 04:47PM
May-14-24 08:30AM
May-09-24 11:51AM
(Investor's Business Daily)
11:51AM
(Investor's Business Daily)
09:45AM
08:30AM
02:35AM
May-08-24 08:30AM
May-07-24 04:15PM
08:30AM
May-06-24 08:30AM
May-04-24 08:00AM
(Investor's Business Daily)
May-03-24 01:15PM
May-02-24 11:18AM
03:01AM
01:06AM
May-01-24 11:36PM
(Thomson Reuters StreetEvents)
09:01PM
04:18PM
(Investor's Business Daily)
11:54AM
09:30AM
09:04AM
(Investor's Business Daily)
08:31AM
08:15AM
07:18AM
(Associated Press Finance)
07:00AM
Apr-30-24 05:48PM
05:45PM
05:31PM
05:12PM
09:15AM
Apr-24-24 10:15AM
(Investor's Business Daily)
10:01AM
08:30AM
08:00AM
Apr-23-24 11:50AM
(Investor's Business Daily)
07:22AM
07:00AM
Apr-22-24 11:10AM
Apr-16-24 04:01PM
02:30AM
Apr-10-24 04:01PM
Apr-09-24 07:37AM
Apr-03-24 08:30AM
Mar-28-24 08:30AM
Mar-24-24 09:19AM
Mar-23-24 08:00AM
(Investor's Business Daily)
Mar-16-24 08:00AM
(Investor's Business Daily)
01:23AM
Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company, which engages in the research, development, and commercialization of pharmaceuticals for the treatment of neurological, neuroendocrine, and neuropsychiatric disorders. The company was founded by Kevin C. Gorman and Wylie W. Vale in January 1992 and is headquartered in San Diego, CA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Boyer David W. Chief Corp. Affairs Officer Sep 13 '24 Sale 121.88 3,461 421,828 1,672 Sep 17 04:21 PM DAVID WARREN BOYER Officer Sep 13 '24 Proposed Sale 121.28 4,756 576,808 Sep 13 04:23 PM RASTETTER WILLIAM H Director Aug 15 '24 Sale 146.69 14,250 2,090,332 37,491 Aug 16 05:00 PM LYONS GARY A Director Aug 13 '24 Option Exercise 42.76 11,570 494,733 130,617 Aug 15 05:21 PM LYONS GARY A Director Aug 13 '24 Sale 150.43 11,570 1,740,450 119,047 Aug 15 05:21 PM ABERNETHY MATT Chief Financial Officer Aug 13 '24 Option Exercise 73.60 14,100 1,037,760 45,628 Aug 15 05:12 PM ABERNETHY MATT Chief Financial Officer Aug 13 '24 Sale 150.38 14,100 2,120,347 31,528 Aug 15 05:12 PM Delaet Ingrid Chief Regulatory Officer Aug 13 '24 Option Exercise 103.52 3,043 315,011 9,650 Aug 15 05:06 PM Delaet Ingrid Chief Regulatory Officer Aug 13 '24 Sale 150.10 7,143 1,072,180 2,507 Aug 15 05:06 PM Delaet Ingrid Chief Regulatory Officer Aug 06 '24 Option Exercise 79.02 273 21,572 6,880 Aug 08 05:16 PM Delaet Ingrid Chief Regulatory Officer Aug 06 '24 Sale 147.70 273 40,322 6,607 Aug 08 05:16 PM Cooke Julie Chief Human Resources Officer Aug 01 '24 Option Exercise 61.82 12,632 780,910 30,834 Aug 05 05:40 PM Cooke Julie Chief Human Resources Officer Aug 01 '24 Sale 153.26 12,632 1,936,017 18,202 Aug 05 05:40 PM Lippoldt Darin Chief Legal Officer Aug 01 '24 Option Exercise 79.02 2,996 236,744 42,736 Aug 05 05:18 PM Lippoldt Darin Chief Legal Officer Aug 01 '24 Sale 154.01 2,996 461,423 39,740 Aug 05 05:18 PM Cooke Julie Chief Human Resources Officer Jul 16 '24 Option Exercise 61.82 900 55,638 19,102 Jul 18 05:12 PM Cooke Julie Chief Human Resources Officer Jul 16 '24 Sale 150.04 900 135,036 18,202 Jul 18 05:12 PM Delaet Ingrid Chief Regulatory Officer Jul 16 '24 Option Exercise 103.52 1,957 202,589 9,064 Jul 18 05:00 PM Delaet Ingrid Chief Regulatory Officer Jul 16 '24 Sale 150.03 2,857 428,627 6,607 Jul 18 05:00 PM LYONS GARY A Director Jul 16 '24 Option Exercise 42.76 930 39,767 119,977 Jul 18 04:54 PM LYONS GARY A Director Jul 16 '24 Sale 150.03 930 139,530 119,047 Jul 18 04:54 PM ABERNETHY MATT Chief Financial Officer Jul 16 '24 Option Exercise 73.60 900 66,240 32,428 Jul 18 04:45 PM ABERNETHY MATT Chief Financial Officer Jul 16 '24 Sale 150.04 900 135,037 31,528 Jul 18 04:45 PM Lippoldt Darin Chief Legal Officer Jul 16 '24 Option Exercise 79.02 7,004 553,456 46,744 Jul 18 04:41 PM Lippoldt Darin Chief Legal Officer Jul 16 '24 Sale 150.00 7,004 1,050,590 39,740 Jul 18 04:41 PM Cooke Julie Chief Human Resources Officer Jul 01 '24 Option Exercise 61.82 10,000 618,200 28,202 Jul 02 09:36 PM Cooke Julie Chief Human Resources Officer Jul 01 '24 Sale 140.19 10,000 1,401,864 18,202 Jul 02 09:36 PM Delaet Ingrid Chief Regulatory Officer Jul 01 '24 Option Exercise 79.02 272 21,493 7,779 Jul 02 09:09 PM Delaet Ingrid Chief Regulatory Officer Jul 01 '24 Sale 138.11 272 37,566 7,507 Jul 02 09:09 PM Delaet Ingrid Chief Regulatory Officer May 31 '24 Option Exercise 79.02 273 21,572 7,780 Jun 04 04:23 PM Delaet Ingrid Chief Regulatory Officer May 31 '24 Sale 136.55 273 37,278 7,507 Jun 04 04:23 PM SHERWIN STEPHEN A Director May 29 '24 Option Exercise 44.68 40,000 1,787,350 51,504 May 30 04:38 PM SHERWIN STEPHEN A Director May 29 '24 Sale 133.46 40,000 5,338,564 26,504 May 30 04:38 PM Sharp Shalini Director May 17 '24 Option Exercise 0.00 2,100 0 2,100 May 21 05:35 PM Sharp Shalini Director May 17 '24 Sale 141.90 1,106 156,943 994 May 21 05:35 PM POPS RICHARD F Director May 17 '24 Option Exercise 0.00 4,199 0 33,711 May 21 05:27 PM POPS RICHARD F Director May 17 '24 Sale 141.84 2,100 297,860 31,611 May 21 05:27 PM MORROW GEORGE J Director May 17 '24 Option Exercise 0.00 4,199 0 4,199 May 21 05:15 PM Norwalk Leslie V Director May 17 '24 Option Exercise 0.00 2,100 0 2,100 May 21 05:06 PM Norwalk Leslie V Director May 17 '24 Sale 141.82 1,106 156,850 994 May 21 05:06 PM LYONS GARY A Director May 17 '24 Option Exercise 0.00 2,100 0 119,047 May 21 04:57 PM SHERWIN STEPHEN A Director May 17 '24 Option Exercise 0.00 4,199 0 26,504 May 21 04:51 PM Mercier Johanna Director May 17 '24 Option Exercise 0.00 2,100 0 2,100 May 21 04:46 PM LYONS GARY A Director May 14 '24 Option Exercise 42.76 12,500 534,500 129,447 May 16 04:55 PM LYONS GARY A Director May 14 '24 Sale 135.63 12,500 1,695,370 116,947 May 16 04:55 PM ABERNETHY MATT Chief Financial Officer May 14 '24 Option Exercise 73.60 15,000 1,104,000 46,528 May 16 04:40 PM ABERNETHY MATT Chief Financial Officer May 15 '24 Option Exercise 73.60 15,000 1,104,000 46,528 May 16 04:40 PM ABERNETHY MATT Chief Financial Officer May 15 '24 Sale 140.24 15,000 2,103,609 31,528 May 16 04:40 PM ABERNETHY MATT Chief Financial Officer May 14 '24 Sale 135.66 15,000 2,034,826 31,528 May 16 04:40 PM Delaet Ingrid Chief Regulatory Officer May 06 '24 Option Exercise 79.02 273 21,572 7,780 May 08 04:26 PM Delaet Ingrid Chief Regulatory Officer May 06 '24 Sale 140.55 273 38,370 7,507 May 08 04:26 PM BENEVICH ERIC Chief Commercial Officer Apr 15 '24 Option Exercise 81.21 19,818 1,609,431 53,365 Apr 17 05:19 PM BENEVICH ERIC Chief Commercial Officer Apr 15 '24 Sale 133.36 19,818 2,643,020 40,778 Apr 17 05:19 PM Delaet Ingrid Chief Regulatory Officer Apr 01 '24 Option Exercise 79.02 272 21,493 7,779 Apr 03 04:44 PM Delaet Ingrid Chief Regulatory Officer Apr 01 '24 Sale 137.30 272 37,346 7,507 Apr 03 04:44 PM Delaet Ingrid Chief Regulatory Officer Mar 21 '24 Option Exercise 103.52 5,000 517,600 12,507 Mar 25 06:02 PM Delaet Ingrid Chief Regulatory Officer Mar 21 '24 Sale 145.06 5,000 725,320 7,507 Mar 25 06:02 PM BENEVICH ERIC Chief Commercial Officer Mar 14 '24 Option Exercise 80.90 75,000 6,067,628 110,299 Mar 15 05:33 PM BENEVICH ERIC Chief Commercial Officer Mar 14 '24 Sale 139.38 75,000 10,453,417 40,778 Mar 15 05:33 PM MORROW GEORGE J Director Mar 14 '24 Option Exercise 39.79 40,000 1,591,600 20,000 Mar 15 05:25 PM MORROW GEORGE J Director Mar 14 '24 Sale 139.42 40,000 5,576,710 0 Mar 15 05:25 PM POPS RICHARD F Director Mar 13 '24 Option Exercise 42.76 23,200 992,032 52,712 Mar 15 05:19 PM POPS RICHARD F Director Mar 13 '24 Sale 140.33 23,200 3,255,621 29,512 Mar 15 05:19 PM Delaet Ingrid Chief Regulatory Officer Mar 13 '24 Option Exercise 106.02 3,000 318,060 10,507 Mar 15 05:15 PM Delaet Ingrid Chief Regulatory Officer Mar 13 '24 Sale 140.14 3,000 420,419 7,507 Mar 15 05:15 PM POPS RICHARD F Director Mar 08 '24 Option Exercise 42.76 1,700 72,692 31,212 Mar 12 06:47 PM POPS RICHARD F Director Mar 11 '24 Option Exercise 42.76 100 4,276 29,612 Mar 12 06:47 PM POPS RICHARD F Director Mar 08 '24 Sale 140.05 1,700 238,078 29,512 Mar 12 06:47 PM POPS RICHARD F Director Mar 11 '24 Sale 140.00 100 14,000 29,512 Mar 12 06:47 PM Delaet Ingrid Chief Regulatory Officer Mar 08 '24 Option Exercise 106.02 1,800 190,836 9,307 Mar 12 06:38 PM Delaet Ingrid Chief Regulatory Officer Mar 11 '24 Option Exercise 106.02 200 21,204 7,707 Mar 12 06:38 PM Delaet Ingrid Chief Regulatory Officer Mar 08 '24 Sale 140.03 1,800 252,053 7,507 Mar 12 06:38 PM Delaet Ingrid Chief Regulatory Officer Mar 11 '24 Sale 140.00 200 28,000 7,507 Mar 12 06:38 PM Delaet Ingrid Chief Regulatory Officer Feb 28 '24 Option Exercise 79.02 6,544 517,107 10,007 Feb 29 07:02 PM Delaet Ingrid Chief Regulatory Officer Feb 29 '24 Option Exercise 79.02 273 21,572 7,780 Feb 29 07:02 PM Delaet Ingrid Chief Regulatory Officer Feb 28 '24 Sale 135.34 6,544 885,638 7,507 Feb 29 07:02 PM Delaet Ingrid Chief Regulatory Officer Feb 29 '24 Sale 135.51 273 36,994 7,507 Feb 29 07:02 PM BENEVICH ERIC Chief Commercial Officer Feb 28 '24 Option Exercise 53.67 75,000 4,025,043 93,759 Feb 29 06:55 PM BENEVICH ERIC Chief Commercial Officer Feb 28 '24 Sale 134.69 75,000 10,101,608 40,616 Feb 29 06:55 PM Norwalk Leslie V Director Feb 27 '24 Option Exercise 84.95 8,000 679,600 8,000 Feb 29 06:50 PM Norwalk Leslie V Director Feb 27 '24 Sale 135.67 8,000 1,085,388 0 Feb 29 06:50 PM POPS RICHARD F Director Feb 20 '24 Option Exercise 12.98 15,000 194,700 44,512 Feb 22 05:11 PM POPS RICHARD F Director Feb 20 '24 Sale 132.47 15,000 1,987,047 29,512 Feb 22 05:11 PM ROBERTS EIRY Chief Medical Officer Feb 13 '24 Sale 132.96 1,114 148,122 23,716 Feb 15 05:51 PM Onyia Jude Chief Scientific Officer Feb 13 '24 Sale 132.94 1,432 190,371 13,128 Feb 15 05:48 PM Lippoldt Darin Chief Legal Officer Feb 13 '24 Sale 132.99 1,098 146,028 39,740 Feb 15 05:45 PM GORMAN KEVIN CHARLES Chief Executive Officer Feb 13 '24 Sale 133.02 2,832 376,700 514,596 Feb 15 05:43 PM Gano Kyle Chief Business Development Off Feb 13 '24 Sale 132.89 1,352 179,674 135,166 Feb 15 05:40 PM Delaet Ingrid Chief Regulatory Officer Feb 13 '24 Sale 133.03 716 95,253 7,507 Feb 15 05:38 PM Cooke Julie Chief Human Resources Officer Feb 13 '24 Sale 133.04 796 105,902 17,976 Feb 15 05:35 PM Boyer David W. Chief Corp. Affairs Officer Feb 13 '24 Sale 133.07 1,811 240,996 4,895 Feb 15 05:33 PM BENEVICH ERIC Chief Commercial Officer Feb 13 '24 Sale 133.01 1,098 146,050 40,616 Feb 15 05:29 PM ABERNETHY MATT Chief Financial Officer Feb 13 '24 Sale 132.85 1,352 179,612 31,528 Feb 15 05:27 PM GORMAN KEVIN CHARLES Chief Executive Officer Feb 13 '24 Option Exercise 39.28 5,090 199,951 512,052 Feb 14 05:17 PM Boyer David W. Chief Corp. Affairs Officer Feb 08 '24 Sale 135.41 1,328 179,830 4,895 Feb 08 07:46 PM Boyer David W. Chief Corp. Affairs Officer Feb 06 '24 Sale 141.96 456 64,734 4,894 Feb 08 07:46 PM Cooke Julie Chief Human Resources Officer Feb 08 '24 Sale 135.44 1,329 179,995 17,263 Feb 08 07:35 PM Cooke Julie Chief Human Resources Officer Feb 06 '24 Sale 142.07 1,215 172,617 17,263 Feb 08 07:35 PM ROBERTS EIRY Chief Medical Officer Feb 06 '24 Sale 142.24 1,121 159,446 21,837 Feb 08 07:28 PM ROBERTS EIRY Chief Medical Officer Feb 08 '24 Sale 134.21 980 131,522 22,717 Feb 08 07:28 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite